Olema Financial Statements From 2010 to 2026

OLMA Stock  USD 25.23  1.19  4.50%   
Olema Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Olema Pharmaceuticals' valuation are provided below:
Market Capitalization
2.1 B
Earnings Share
(1.76)
We have found one hundred twenty available trending fundamental ratios for Olema Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Olema Pharmaceuticals recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 23, 2026, Market Cap is expected to decline to about 374.2 M. In addition to that, Enterprise Value is expected to decline to about 223.3 M
Check Olema Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Olema Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Interest Income of 15.3 M or Depreciation And Amortization of 474.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.79. Olema financial statements analysis is a perfect complement when working with Olema Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Olema Stock
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

Olema Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets544.6 M518.6 M157.4 M
Slightly volatile
Other Current Liabilities43.6 M41.5 M9.8 M
Slightly volatile
Total Current Liabilities50.4 M48 M11.5 M
Slightly volatile
Property Plant And Equipment Net2.2 M2.4 M1.1 M
Slightly volatile
Accounts Payable5.4 M5.1 M1.2 M
Slightly volatile
Cash92.3 M160.4 M50.9 M
Slightly volatile
Non Current Assets Total15.1 M14.4 M3.8 M
Slightly volatile
Non Currrent Assets Other11.8 M11.2 M2.6 M
Slightly volatile
Other Assets0.860.920.3 M
Pretty Stable
Cash And Short Term Investments524.2 M499.2 M151.6 M
Slightly volatile
Common Stock Shares Outstanding43.5 M67.6 M29.5 M
Slightly volatile
Liabilities And Stockholders Equity544.6 M518.6 M157.4 M
Slightly volatile
Non Current Liabilities Total219.7 K231.3 K5.9 M
Slightly volatile
Other Current Assets2.7 M2.6 M1.4 M
Slightly volatile
Total Liabilities50.7 M48.3 M17.3 M
Slightly volatile
Property Plant And Equipment Gross2.3 M2.4 M1.2 M
Slightly volatile
Total Current Assets529.5 M504.2 M153.5 M
Slightly volatile
Common Stock7.2 K6.9 K2.5 K
Slightly volatile
Property Plant Equipment1.4 M1.7 M740.5 K
Slightly volatile
Common Stock Total Equity2.4 K2.7 K2.9 K
Slightly volatile
Short and Long Term Debt Total1.9 M1.3 M2.9 M
Slightly volatile
Current Deferred Revenue6.1 M6.9 M7.6 M
Slightly volatile
Net Receivables2.6 M2.4 M568.8 K
Slightly volatile
Capital Surpluse438.5 M469.6 M400 M
Slightly volatile
Non Current Liabilities Other1.6 M1.4 M2.1 M
Slightly volatile
Short Term Debt1.1 M1.3 M989.6 K
Slightly volatile
Intangible Assets546.4 K614.7 K670.9 K
Slightly volatile

Olema Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income15.3 M14.6 MM
Slightly volatile
Depreciation And Amortization474.5 K451.9 K135.9 K
Slightly volatile
Selling General Administrative14.2 M20.4 M7.5 M
Slightly volatile
Other Operating Expenses171.8 M163.6 M47.4 M
Slightly volatile
Research Development150.4 M143.2 M39.4 M
Slightly volatile
Cost Of Revenue647.3 K451.9 K310.9 K
Slightly volatile
Total Operating Expenses171.8 M163.6 M47.4 M
Slightly volatile
Reconciled Depreciation474.5 K451.9 K136.3 K
Slightly volatile
Non Operating Income Net Other1.4 M2.5 M900.1 K
Slightly volatile
Selling And Marketing Expenses301.6 K339.3 K370.3 K
Slightly volatile

Olema Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow70.4 M78.8 M35.2 M
Slightly volatile
Other Cashflows From Financing Activities2.2 M2.3 M21.8 M
Very volatile
Depreciation647.3 K451.9 K310.7 K
Slightly volatile
Total Cash From Financing Activities128.7 M241.9 M90.5 M
Slightly volatile
End Period Cash Flow92.3 M160.4 M50.9 M
Slightly volatile
Change To Netincome22.7 M21.7 M7.5 M
Slightly volatile
Dividends Paid2.5 M2.8 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.440.473.4638
Slightly volatile
Payables Turnover0.01670.01760.0447
Slightly volatile
Cash Per Share3.936.652.7505
Slightly volatile
Days Payables Outstanding17.8 K21.5 K14.3 K
Slightly volatile
Income Quality0.90.930.9132
Slightly volatile
Intangibles To Total Assets0.00120.00140.0015
Slightly volatile
Net Debt To EBITDA1.061.121.941
Very volatile
Current Ratio11.4712.0818.2994
Very volatile
Debt To Equity0.00380.0040.0101
Slightly volatile
Capex Per Share0.0030.00310.0045
Pretty Stable
Interest Debt Per Share0.03250.02190.0194
Slightly volatile
Debt To Assets0.00350.00360.0097
Slightly volatile
Days Of Payables Outstanding17.8 K21.5 K14.3 K
Slightly volatile
Ebt Per Ebit1.081.051.0277
Slightly volatile
Total Debt To Capitalization0.00380.0040.01
Slightly volatile
Debt Equity Ratio0.00380.0040.0101
Slightly volatile
Quick Ratio11.4712.0818.2994
Very volatile
Cash Ratio3.653.8413.6383
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.151.0194
Slightly volatile
Debt Ratio0.00350.00360.0097
Slightly volatile

Olema Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap374.2 M393.8 M1.4 B
Slightly volatile
Enterprise Value223.3 M235.1 M1.1 B
Slightly volatile

Olema Fundamental Market Drivers

Olema Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Olema Pharmaceuticals Financial Statements

Olema Pharmaceuticals stakeholders use historical fundamental indicators, such as Olema Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Olema Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Olema Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Olema Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Olema Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue6.9 M6.1 M
Cost Of Revenue451.9 K647.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.76)
Return On Assets
(0.34)
Return On Equity
(0.59)
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.